Molina Healthcare Q3 2026 Earnings: The $0.89 Quarter Betting on a Medicaid Turn

On October 21, 2026, Molina Healthcare (NYSE: MOH) reported third-quarter GAAP earnings of $0.73 per diluted share and adjusted earnings of $0.89, on premium revenue of $10.5 billion (−3.5%), and reaffirmed full-year guidance of at least $5.25 adjusted per share. The quarter's thesis fits in one CEO sentence: "With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins." Read it carefully — "apparent," "remains at elevated levels," "likely observing" — because the numbers give management's caution its due: the consolidated medical care ratio rose 30 basis points to 92.9%, net income fell 52% to $38 million, and Marketplace membership collapsed by nearly two-thirds. This is the quarter a Medicaid insurer asked investors to look through the worst trailing twelve months in its recent history — an LTM net loss of $48 million — and see the plateau underneath.

The Headline Numbers​

Molina's fiscal year is the calendar year; Q3 2026 ended September 30, 2026. Every figure below comes from the Form 8-K and its earnings release (Exhibit 99.1), cross-checked against the Form 10-Q filed the next day, which carries identical statements.

Read the table as a demonstration of operating leverage running in reverse. Revenue fell $395 million and medical costs fell only $325 million — the 30-basis-point MCR increase means care costs refused to shrink as fast as premiums — so operating income fell $31 million, or 22.6%, on a 3.4% revenue decline. Then the tax line doubled the pain: Q3 2025's effective rate was an unusually low 10.2%, while this quarter's 28.3% is above the statutory rate, so pre-tax income fell 40% and net income fell 52%. The G&A line deserves credit — down 2.6% in dollars, flat at 6.4% of revenue, "reflecting continued operating discipline" — but discipline on 6.4% of revenue cannot offset drift on 92.9% of premiums. Below the line, 1.0 million fewer diluted shares (−1.9%, the buyback overhang from 2025) barely dented the EPS decline.

The GAAP-to-adjusted bridge, straight from the release's reconciliation:

Note how clean this bridge is: a single $10 million recurring add-back, the amortization of acquired intangibles, and nothing else. The $93 million impairment from exiting the traditional Medicare Advantage prescription-drug product sits entirely in the first half — none of it is in this quarter — and there were no acquisition costs at all. At $8 million net of tax, the adjustment is smaller than last year's $18 million, which means the "adjusted" number this quarter is barely adjusted. When a company reports a 52% decline on a nearly GAAP-pure number, there is nowhere to hide and nothing hidden.

Revenue Deep Dive​

Molina discloses three real segments plus an immaterial Other, and the quarter's thesis is that Medicaid — 78% of premiums — held its ground on revenue while Marketplace fell off a cliff and Medicare quietly improved.

Medicaid is the company, so start here: premium revenue grew 2.3% on rate updates that more than offset lower membership, but medical margin fell nearly 10% because the MCR rose 100 basis points to 93.0%. The release calls this "in line with the Company's expectations, reflecting rate updates and stable medical cost trend" — and that word "stable" is doing the work of the whole investment thesis. A 93.0% ratio that is stable at least stops getting worse; the CEO's "beginning of the turn" language hangs on this segment holding 93% while 2027 rates, which he calls strong, catch up. Every dollar of Medicaid margin is earned on 7 cents of premium, so the turn he describes is worth roughly $82 million of annual margin per 100 basis points of ratio improvement — the single most valuable number in the release if it materializes.

Medicare is the quiet beat inside a loud miss: revenue essentially flat, margin up nearly 10%, MCR down 60 basis points to 93.0% on "stable medical cost trend." This is the segment Molina is surgically reshaping — it exited traditional MAPD in thirteen states in 2025 and will exit the product entirely for 2027 to focus on dual-eligible members — and the ratio improvement suggests the pruning is working. Membership fell 16.5% year over year to 222,000, yet margin grew: fewer, better members.

Marketplace is a segment being wound down in all but name. Premium revenue nearly halved (−46.4%) and membership collapsed 62.6% to 267,000, the combined result of pricing strategy, prior-year member reconciliations and CMS program-integrity initiatives that disenrolled members while Molina still covered their claims. Paradoxically the MCR improved 310 basis points to 92.5% — shedding the worst risks first flatters the ratio — but a $48 million margin on a shrinking $642 million base is a melting ice cube. At 6% of premiums, down from 11% a year ago, Marketplace no longer moves the consolidated ratio much either way.

The membership table behind the revenue makes the pricing thesis explicit:

Total membership fell 766,000 (−13.6%) while premium revenue fell only 3.5%. That gap is rates and mix doing heavy lifting — per-member premium rose roughly 12% — and it is the ledger confirmation of management's pricing language. In a managed-care company, "rate updates" is the selling-price theme, and the CEO's "strength of recent rate updates for 2027" is this quarter's pricing signal. It is confirmed, not contradicted, by the heads-versus-dollars arithmetic. What is absent matters too: there is no demand-side language anywhere in the release — no growth story, no expansion, no robust anything — because when your membership falls 13.6% by design and by disenrollment, demand is not the story. Rates are.

The Margin Story​

(Annual ratios from the 10-Ks; MCR is medical care costs ÷ premium revenue, G&A ratio is G&A ÷ total revenue per the release's definition.)

The multi-year picture is a three-year underwriting squeeze that has not yet turned — only, perhaps, plateaued. The MCR deteriorated 480 basis points from FY2023 (88.1%) to this quarter (92.9%), and the damage compounds down the income statement: pre-tax margin collapsed from 4.3% to 0.5%, net margin from 3.2% to 0.3%. Molina's own 10-K quantifies the leverage — one point of MCR moves annual diluted EPS by roughly $6 — so the 260-basis-point FY2025 deterioration alone explains most of the $20.42-to-$8.92 EPS collapse. Against that, G&A discipline is real but small: 80 basis points of improvement over three years against 480 of MCR damage. This is the arithmetic of a fixed-premium business with a narrow margin: costs set the outcome, and everything else is commentary.

But look at the rate of change, because that is where the plateau lives. The MCR rose 100 basis points in FY2024, 260 in FY2025 — and 30 this quarter. Each segment's ratio was "in line with expectations," Medicare's actually improved, and the CEO named the mechanism: "plateauing of medical cost trend" plus "strength of recent rate updates for 2027." The bull case is that +30 basis points after +260 is the turn beginning. The bear case is that 92.9% is still the worst ratio in this table, "elevated levels" is management's own description, and one quarter of deceleration is a data point, not a turn. Both cases agree on the number to watch: Q4's MCR, which must hold near 93% — and then fall in 2027 — for the guidance to work.

The One Big Question: Can a $5.25 Guide Survive a $48 Million Trailing Loss?​

Start with the trailing twelve months, because they frame everything. LTM net income is negative $48 million: nine-month 2026 earned $112 million, but Q4 2025 — derived as the FY2025 annual less nine-month 2025, all exact differences of filed figures — lost $160 million on a 94.6% implied MCR, the quarter the California retroactive premium items and Marketplace deterioration hit together. Against that hole, management reaffirmed at least $5.25 of adjusted EPS for 2026, roughly $270 million of adjusted net income. The bridge from a $48 million trailing GAAP loss to $270 million of adjusted profit has three spans, and the release's own guidance reconciliation itemizes them.

First, the add-backs are genuinely one-time: the $93 million MAPD-exit impairment, $48 million of acquisition costs, $21 million of termination benefits. None recurs once the MAPD exit completes. Second, the GAAP guide itself — $122 million, or $2.38 — requires Q4 to earn just $10 million (nine months already delivered $112 million), even after absorbing what the release quantifies as a $1.50-per-share loss from implementing the new Florida Medicaid contract in Q4 plus a $1.00-per-share loss on the traditional MAPD product being exited. That is $2.50 of known Q4 headwinds, roughly $128 million pre-tax, which means the underlying Q4 run-rate the guide implies is a number the company has not printed since 2024. Third, the share count: 51.4 million assumed diluted shares, down from 57.7 million in FY2024 on buybacks, mechanically lifts every per-share figure 12% versus two years ago.

The peer comparison sharpens the stakes. Elevance reported the same morning: a 90.6% benefit ratio down 70 basis points, adjusted EPS of $6.99 up 15.9%, and raised guidance. Molina's ratio went the wrong way (+30 bp), its EPS fell by half, and it held guidance only by pointing at 2027 rates. Same industry, same medical-cost environment, opposite quarters — which means Molina's 92.9% is substantially a company problem (Medicaid concentration, Marketplace exits, the Florida transition), not just an industry one. The Florida contract deserves its own watch item: a $1.50-per-share implementation loss is the price of a growth asset, but new Medicaid contracts have a history across the industry of underpricing the first year. If Florida's members arrive sicker than priced — the same acuity surprise that drove 2025's deterioration — the implementation loss becomes an ongoing MCR headwind in Molina's largest segment.

Tracking an $11 Billion Insurer in Plain Text​

A health insurer is a float business wearing a healthcare costume — premiums arrive before claims are paid, and the $4,988 million medical-claims-payable reserve is the timing difference made visible — and modeling it in Beancount forces every dollar of that float to reconcile. Our open ledger reconstructs Molina line by line from its own filings — read how we model every company for the shared conventions. Income is negative (credit), expenses positive (debit), and the transaction sums to zero:

; FY2026Q3 Income Statement — quarter ended September 30, 2026
; Check: −11082 + 9719 + 710 + 500 + 38 + 9 + 53 + 15 + 38 = 0 ✓
 
2026-09-30 * "Molina Healthcare, Inc." "FY2026Q3 Income Statement"
  Income:Revenue                         -11082 MUSD  ; premium revenue 10,457 + premium tax revenue 500 + investment income 102 + other revenue 23
  Expenses:CostOfRevenue                     9719 MUSD  ; medical care costs (MCR 92.9%; includes $352M favorable prior-year development YTD)
  Expenses:SellingGeneralAdministrative       710 MUSD  ; general and administrative expenses (G&A ratio 6.4%)
  Expenses:OtherNet                           500 MUSD  ; premium tax expenses (pass-through; equals premium tax revenue)
  Expenses:DepreciationAndAmortization         38 MUSD  ; depreciation and amortization
  Expenses:OtherNet                             9 MUSD  ; other operating expenses
  Expenses:Interest                            53 MUSD  ; interest expense
  Expenses:IncomeTax                           15 MUSD  ; income tax expense
  Equity:Adjustments                           38 MUSD  ; net income offset (RE set by balance assertion)

The balance-sheet number that tells the narrative is $4,988 million of medical claims payable, up just $101 million (+2.1%) since year-end while nine-month medical costs ran at a $37.9 billion annualized pace. That reserve growing far slower than the cost base is the mirror of the plateau story: Days in Claims Payable held at 44, flat with June and down from 46 a year ago, which means Molina is not stretching provider payments to flatter the ratio — the anti-Elevance tell, where DCP stretched 3.5 days. The second tell sits inside the reserve roll-forward: $352 million of favorable prior-year development over nine months, nearly triple last year's $124 million, meaning Molina entered 2026 reserved conservatively and is releasing it as claims settle. Conservative reserving plus flat DCP is the combination that lets you trust a 92.9% ratio at face value. The third tell is cash: nine-month operating cash flow of $629 million against $112 million of net income — a 5.6x conversion — as government receivable and payable settlements normalized, and parent-company cash nearly tripled to $608 million. The P&L is ugly; the balance sheet is healing. Watch DCP against the MCR each quarter: if the ratio falls while DCP holds near 44, the turn is underwriting, not timing.

The Multi-Year Arc​

(LTM = nine months 2026 plus Q4 2025, where Q4 2025 is the FY2025 annual less nine-month 2025 from the release: revenue $11,375 million, a net loss of $160 million, medical costs $10,136 million on premiums of $10,715 million for a 94.6% implied MCR. All exact differences of filed figures. The ledger itself starts at FY2024 — two audited annuals plus the current quarter — with FY2023 shown here from 10-K comparatives for context.)

The arc is revenue without profit: total revenue up 33% from FY2023 to FY2025 while net income fell 57%, because the MCR ate 360 basis points faster than G&A discipline gave back 60. Premiums did the revenue work — the ConnectiCare acquisition, rate increases, contract wins — while redeterminations shrank Medicaid heads and acuity rose among those who remained. The LTM column looks worse than FY2025 on every line because it carries the $160 million Q4 2025 loss; strip that one quarter and LTM net income is roughly $112 million of clean 2026 earnings, the number the $5.25 guide needs Q4 to build on. That is the bull case in one sentence: the revenue machine works, the Q4 2025 loss was the kitchen-sink quarter, and if the MCR has genuinely plateaued at 93%, 2027 rates flow straight to a margin that has nowhere to go but up. The bear case is the same table read left to right: three years of medical costs outrunning premiums is a trend, LTM earnings are negative, and one quarter of +30 basis points after +260 is a deceleration, not a turn.

The Verdict: Bull vs. Bear​

Bull Case

• The cost trend is plateauing where it matters: Medicaid MCR stable at 93.0% "in line with expectations," Medicare improving 60 bp to 93.0%, and the CEO citing "strength of recent rate updates for 2027" — rates catching up to costs is the whole thesis.
• The ratio is trustworthy: DCP flat at 44 (down from 46 a year ago) with $352 million of favorable prior-year development, nearly triple last year — conservative reserving, not reserve stretching.
• The quarter is GAAP-pure: a single $10 million amortization add-back separates $0.73 from $0.89, the $93 million impairment sits in H1, and there is no acquisition noise — the miss is honest, which makes the turn legible.
• Cash says the business works: $629 million of nine-month operating cash flow (5.6x net income), parent cash nearly tripled to $608 million, and the share count down 12% in two years — every 2027 margin dollar lands on fewer shares.
• The bad books are being exited, not fixed: traditional MAPD gone for 2027 after its $93 million farewell impairment, Marketplace shrunk 63% by heads — the remaining premium base is higher-quality by construction.

Bear Case

• 92.9% is still the worst ratio in the table: +30 basis points extends the streak to three years and 480 basis points, and "remains at elevated levels" is management's own verdict — a plateau at the peak is not a turn.
• The same morning indicted the company story: Elevance's benefit ratio fell 70 bp while Molina's rose 30 bp in the same medical-cost environment — Medicaid concentration and execution, not the industry, explain the gap.
• Q4 carries $2.50 of known per-share headwinds — the $1.50 Florida implementation loss plus $1.00 of MAPD runoff — so the reaffirmed guide needs an underlying Q4 run-rate Molina has not printed since 2024.
• LTM earnings are negative $48 million on a 92.7% ratio: two full years of rate-trend imbalance have to reverse, not merely stop, and state rate updates have lagged costs for three consecutive cycles.
• Membership is shrinking everywhere it counts: Medicaid −5.8%, Medicare −16.5%, Marketplace −62.6% — a rate story works until regulators push back, and the redetermination-driven acuity mix that caused this has not reversed.

Our Take: Believe the plateau, underwrite the turn at a discount. Flat DCP with tripled favorable development is the combination that says 92.9% is real, not managed — and a real 93% with strong 2027 rates behind it is exactly what "the beginning of the turn in Medicaid margins" looks like at the start. But Elevance's same-day improvement proves the environment alone does not explain Molina's quarter, and a guide that needs a clean Q4 through $2.50 of known headwinds is a forecast, not a floor. At $5.25 of promised adjusted EPS against $2.19 earned over nine months, Q4 must deliver roughly $3.06 — net of Florida and MAPD — which is more than the entire first nine months combined. Watch Q4's MCR and DCP together: a ratio at or below 93% with days-payable steady near 44 confirms the turn is underwriting; a ratio back above 94% confirms the bears, and no rate update in 2027 will save the guide.